Biote Corp. Appoints New Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: NASDAQ.COM
- Executive Appointment: Biote Corp. announced the appointment of Komal Bajaj as Chief Medical Officer, effective June 1, aiming to strengthen the company's medical leadership and innovation capabilities.
- Extensive Experience: Bajaj brings over 20 years of clinical practice and healthcare quality management experience, having served as Chief Quality Officer at NYC Health + Hospitals, which is expected to provide Biote with new perspectives and expertise.
- Succession Context: Bajaj succeeds Ross McQuivey, who has been the Chief Medical Officer since June 2022, and this change may influence the company's strategic direction and quality of medical services.
- Market Reaction: Following the announcement, Biote Corp.'s stock price fell by 1.96% to $2.00 on Nasdaq, indicating market caution regarding the executive transition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BTMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BTMD
About BTMD
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biote Corp. Appoints New Chief Medical Officer
- Executive Appointment: Biote Corp. announced the appointment of Komal Bajaj as Chief Medical Officer, effective June 1, aiming to strengthen the company's medical leadership and innovation capabilities.
- Extensive Experience: Bajaj brings over 20 years of clinical practice and healthcare quality management experience, having served as Chief Quality Officer at NYC Health + Hospitals, which is expected to provide Biote with new perspectives and expertise.
- Succession Context: Bajaj succeeds Ross McQuivey, who has been the Chief Medical Officer since June 2022, and this change may influence the company's strategic direction and quality of medical services.
- Market Reaction: Following the announcement, Biote Corp.'s stock price fell by 1.96% to $2.00 on Nasdaq, indicating market caution regarding the executive transition.
See More
Biote Appoints Interim CEO and Director Amid Leadership Changes
- Executive Changes: Biote announced that CFO and Chief Business Officer Bob Peterson will become interim CEO and Director effective June 8, 2026, succeeding Bret Christensen, who is stepping down for family reasons but will remain on the Board.
- Board Restructuring: Chairman Marc Beer will take over as executive chairman, indicating the company's commitment to stability during this leadership transition while emphasizing the importance of future leadership.
- Financial Guidance Reaffirmed: Biote reaffirmed its FY26 revenue guidance of over $190 million and adjusted EBITDA above $38 million, reflecting confidence in future performance, particularly with expected procedure revenue growth returning in H2 2026.
- Strategic Investment Plans: The company aims to drive growth by expanding its sales force and investing in its tech platform, which is intended to enhance market competitiveness and meet customer demands, thereby solidifying its position in the biotechnology sector.
See More
Biote CEO Bret Christensen Steps Down, CFO Bob Peterson Named Interim CEO
- Leadership Transition: Biote's CEO Bret Christensen has stepped down for family and personal reasons while remaining on the Board, indicating the company's commitment to leadership stability, which may impact investor confidence.
- Interim CEO Appointment: CFO Bob Peterson has been named Interim CEO, expected to continue driving the company's financial strategy and operational scaling, ensuring business continuity during this transition period.
- 2026 Guidance Reaffirmed: Biote reaffirmed its guidance for 2026, projecting revenue above $190 million and Adjusted EBITDA exceeding $38 million, indicating stability and growth potential in the market, which enhances investor confidence.
- Executive Search Underway: The Board has retained an executive search firm to assist in identifying a new CFO, reflecting the company's focus on future leadership and ensuring continued strategic execution and business growth.
See More
Biote (BTMD) Q1 2026 Earnings Call Insights
- Performance Pressure: Biote reported Q1 2026 revenue of $44.9 million, an 8.3% decline year-over-year, with procedure revenue down 13.2% to $31.3 million, primarily impacted by a voluntary recall that resulted in an estimated $1.7 million revenue loss, placing significant financial pressure on the company.
- Sales Team Expansion: Despite the recall challenges, Biote successfully hired 25 new sales personnel and trained over 200 new practitioners in Q1, representing a 16.5% increase from Q1 2025, demonstrating the company's ongoing efforts to enhance market competitiveness.
- Maintained Outlook: CFO Peterson reiterated the full-year revenue target of over $190 million and adjusted EBITDA exceeding $38 million, acknowledging a downward adjustment in first-half procedure revenue expectations, yet remaining optimistic about recovery in the second half of the year.
- Ongoing Recall Impact: Management noted that the recall has distracted the sales team from focusing on growth objectives, with expectations that this impact will continue into Q2; however, they believe it is a temporary issue that will not affect their long-term strategy.
See More
Biote Corp. Q4 2025 Earnings Call Insights
- Sales Team Expansion: Biote Corp. reported that its sales team grew to over 90 members by the end of 2025, up from 60 prior to the reorganization, successfully stabilizing clinic attrition and maximizing new clinic starts, indicating positive progress in rebuilding its commercial team.
- Financial Performance Overview: The fourth quarter revenue was $46.4 million, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million, providing a new revenue stream despite the overall decline in revenue.
- Future Outlook: The company forecasts revenues exceeding $190 million and adjusted EBITDA above $38 million for 2026, with a projected decline in procedure revenue in the first half but anticipated growth in the second half, reflecting management's cautious optimism about future performance.
- Investments and Expenses: Management plans to increase sales personnel to approximately 120 in 2026 and make significant investments in the technology platform, which will lead to a near-term rise in operating expenses but is expected to lay the groundwork for future growth in procedure revenue.
See More
BIOTE Releases Financial Outlook for 2026
- Earnings Highlights: BIOTE's Q4 GAAP EPS of $0.06 exceeded expectations by $0.04, while revenue of $46.4 million, despite a 6.9% year-over-year decline, beat estimates by $0.61 million, demonstrating the company's resilience in challenging conditions.
- 2026 Revenue Outlook: The company anticipates total revenue exceeding $190 million in 2026, with procedure revenue expected to decline at a mid to high single-digit percentage rate in the first half, but projected to return to growth in the second half, indicating potential market recovery.
- Adjusted EBITDA Guidance: BIOTE expects adjusted EBITDA to exceed $38 million in 2026, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability and boosting investor confidence.
- Nutritional Supplements Growth: Revenue from dietary supplements is expected to grow at a mid to high single-digit rate in 2026, indicating the company's strong positioning in the health and nutrition sector to capitalize on the increasing consumer demand for health products.
See More
Biote Corp. Appoints New Chief Medical Officer
- Executive Appointment: Biote Corp. announced the appointment of Komal Bajaj as Chief Medical Officer, effective June 1, aiming to strengthen the company's medical leadership and innovation capabilities.
- Extensive Experience: Bajaj brings over 20 years of clinical practice and healthcare quality management experience, having served as Chief Quality Officer at NYC Health + Hospitals, which is expected to provide Biote with new perspectives and expertise.
- Succession Context: Bajaj succeeds Ross McQuivey, who has been the Chief Medical Officer since June 2022, and this change may influence the company's strategic direction and quality of medical services.
- Market Reaction: Following the announcement, Biote Corp.'s stock price fell by 1.96% to $2.00 on Nasdaq, indicating market caution regarding the executive transition.
See More
Biote Appoints Interim CEO and Director Amid Leadership Changes
- Executive Changes: Biote announced that CFO and Chief Business Officer Bob Peterson will become interim CEO and Director effective June 8, 2026, succeeding Bret Christensen, who is stepping down for family reasons but will remain on the Board.
- Board Restructuring: Chairman Marc Beer will take over as executive chairman, indicating the company's commitment to stability during this leadership transition while emphasizing the importance of future leadership.
- Financial Guidance Reaffirmed: Biote reaffirmed its FY26 revenue guidance of over $190 million and adjusted EBITDA above $38 million, reflecting confidence in future performance, particularly with expected procedure revenue growth returning in H2 2026.
- Strategic Investment Plans: The company aims to drive growth by expanding its sales force and investing in its tech platform, which is intended to enhance market competitiveness and meet customer demands, thereby solidifying its position in the biotechnology sector.
See More
Biote CEO Bret Christensen Steps Down, CFO Bob Peterson Named Interim CEO
- Leadership Transition: Biote's CEO Bret Christensen has stepped down for family and personal reasons while remaining on the Board, indicating the company's commitment to leadership stability, which may impact investor confidence.
- Interim CEO Appointment: CFO Bob Peterson has been named Interim CEO, expected to continue driving the company's financial strategy and operational scaling, ensuring business continuity during this transition period.
- 2026 Guidance Reaffirmed: Biote reaffirmed its guidance for 2026, projecting revenue above $190 million and Adjusted EBITDA exceeding $38 million, indicating stability and growth potential in the market, which enhances investor confidence.
- Executive Search Underway: The Board has retained an executive search firm to assist in identifying a new CFO, reflecting the company's focus on future leadership and ensuring continued strategic execution and business growth.
See More
Biote (BTMD) Q1 2026 Earnings Call Insights
- Performance Pressure: Biote reported Q1 2026 revenue of $44.9 million, an 8.3% decline year-over-year, with procedure revenue down 13.2% to $31.3 million, primarily impacted by a voluntary recall that resulted in an estimated $1.7 million revenue loss, placing significant financial pressure on the company.
- Sales Team Expansion: Despite the recall challenges, Biote successfully hired 25 new sales personnel and trained over 200 new practitioners in Q1, representing a 16.5% increase from Q1 2025, demonstrating the company's ongoing efforts to enhance market competitiveness.
- Maintained Outlook: CFO Peterson reiterated the full-year revenue target of over $190 million and adjusted EBITDA exceeding $38 million, acknowledging a downward adjustment in first-half procedure revenue expectations, yet remaining optimistic about recovery in the second half of the year.
- Ongoing Recall Impact: Management noted that the recall has distracted the sales team from focusing on growth objectives, with expectations that this impact will continue into Q2; however, they believe it is a temporary issue that will not affect their long-term strategy.
See More
Biote Corp. Q4 2025 Earnings Call Insights
- Sales Team Expansion: Biote Corp. reported that its sales team grew to over 90 members by the end of 2025, up from 60 prior to the reorganization, successfully stabilizing clinic attrition and maximizing new clinic starts, indicating positive progress in rebuilding its commercial team.
- Financial Performance Overview: The fourth quarter revenue was $46.4 million, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million, providing a new revenue stream despite the overall decline in revenue.
- Future Outlook: The company forecasts revenues exceeding $190 million and adjusted EBITDA above $38 million for 2026, with a projected decline in procedure revenue in the first half but anticipated growth in the second half, reflecting management's cautious optimism about future performance.
- Investments and Expenses: Management plans to increase sales personnel to approximately 120 in 2026 and make significant investments in the technology platform, which will lead to a near-term rise in operating expenses but is expected to lay the groundwork for future growth in procedure revenue.
See More
BIOTE Releases Financial Outlook for 2026
- Earnings Highlights: BIOTE's Q4 GAAP EPS of $0.06 exceeded expectations by $0.04, while revenue of $46.4 million, despite a 6.9% year-over-year decline, beat estimates by $0.61 million, demonstrating the company's resilience in challenging conditions.
- 2026 Revenue Outlook: The company anticipates total revenue exceeding $190 million in 2026, with procedure revenue expected to decline at a mid to high single-digit percentage rate in the first half, but projected to return to growth in the second half, indicating potential market recovery.
- Adjusted EBITDA Guidance: BIOTE expects adjusted EBITDA to exceed $38 million in 2026, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability and boosting investor confidence.
- Nutritional Supplements Growth: Revenue from dietary supplements is expected to grow at a mid to high single-digit rate in 2026, indicating the company's strong positioning in the health and nutrition sector to capitalize on the increasing consumer demand for health products.
See More
